Delhi: Dr Dangs Lab to be 1st central lab to hold human trials of Covaxine
Advertisement
Delhi: A Delhi-based private laboratory has claimed that it has been selected as the central lab for human clinical trials of Covaxin, India's indigenous COVID-19 vaccine candidate. The vaccine is being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.
Dr. Dangs Lab said on Wednesday that it has partnered with Bharat Biotech for conducting the trials."We are extremely privileged to announce that Dr. Dangs Lab, New Delhi has been provided the opportunity to serve the nation by being selected as the central lab for the Human Clinical trials of Covaxin; India's indigenous COVID-19 vaccine being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology " it said in a statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.